Literature DB >> 15353342

Cellular immunity and immunotherapy of brain tumors.

Robert M Prins1, Linda M Liau.   

Abstract

Factors influencing the host immune response to central nervous system (CNS) tumors are not yet well understood. This review will outline what is known about anti-tumor immune responses against CNS tumors and describe how advances in our knowledge of basic immunology may be applied to brain tumor immunotherapy. We will first focus on cellular immune system interactions involved in peripheral anti-tumor immune responses. Then, we will discuss characteristics of tumors arising within the confines of the CNS that distinguish them from peripheral neoplasms, emphasizing immune defects that seem to limit or curtail specific anti-tumor immunity against brain tumors. Finally, the current state of immune-based treatment paradigms and future directions will be discussed, paying particular attention to adoptive cellular immunotherapy and tumor vaccine approaches for the treatment of malignant gliomas.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15353342     DOI: 10.2741/1465

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  8 in total

1.  Enhanced sensitivity to IL-2 signaling regulates the clinical responsiveness of IL-12-primed CD8(+) T cells in a melanoma model.

Authors:  Dominique N Lisiero; Horacio Soto; Linda M Liau; Robert M Prins
Journal:  J Immunol       Date:  2011-03-23       Impact factor: 5.422

Review 2.  Medulloblasoma: challenges for effective immunotherapy.

Authors:  Adam M Sonabend; Alfred T Ogden; Lisa M Maier; David E Anderson; Peter Canoll; Jeffrey N Bruce; Richard C E Anderson
Journal:  J Neurooncol       Date:  2011-12-16       Impact factor: 4.130

Review 3.  Current immunotherapeutic strategies for central nervous system tumors.

Authors:  Medina C Kushen; Adam M Sonabend; Maciej S Lesniak
Journal:  Surg Oncol Clin N Am       Date:  2007-10       Impact factor: 3.495

Review 4.  Immunotherapeutic approaches for glioma.

Authors:  Hideho Okada; Gary Kohanbash; Xinmei Zhu; Edward R Kastenhuber; Aki Hoji; Ryo Ueda; Mitsugu Fujita
Journal:  Crit Rev Immunol       Date:  2009       Impact factor: 2.214

5.  Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain.

Authors:  Robert M Prins; Chengyi J Shu; Caius G Radu; Dan D Vo; Haumith Khan-Farooqi; Horacio Soto; Meng-Yin Yang; Muh-Shi Lin; Stephanie Shelly; Owen N Witte; Antoni Ribas; Linda M Liau
Journal:  Cancer Immunol Immunother       Date:  2008-02-06       Impact factor: 6.968

6.  First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.

Authors:  Linda M Liau; Keyoumars Ashkan; David D Tran; Jian L Campian; John E Trusheim; Charles S Cobbs; Jason A Heth; Michael Salacz; Sarah Taylor; Stacy D D'Andre; Fabio M Iwamoto; Edward J Dropcho; Yaron A Moshel; Kevin A Walter; Clement P Pillainayagam; Robert Aiken; Rekha Chaudhary; Samuel A Goldlust; Daniela A Bota; Paul Duic; Jai Grewal; Heinrich Elinzano; Steven A Toms; Kevin O Lillehei; Tom Mikkelsen; Tobias Walbert; Steven R Abram; Andrew J Brenner; Steven Brem; Matthew G Ewend; Simon Khagi; Jana Portnow; Lyndon J Kim; William G Loudon; Reid C Thompson; David E Avigan; Karen L Fink; Francois J Geoffroy; Scott Lindhorst; Jose Lutzky; Andrew E Sloan; Gabriele Schackert; Dietmar Krex; Hans-Jorg Meisel; Julian Wu; Raphael P Davis; Christopher Duma; Arnold B Etame; David Mathieu; Santosh Kesari; David Piccioni; Manfred Westphal; David S Baskin; Pamela Z New; Michel Lacroix; Sven-Axel May; Timothy J Pluard; Victor Tse; Richard M Green; John L Villano; Michael Pearlman; Kevin Petrecca; Michael Schulder; Lynne P Taylor; Anthony E Maida; Robert M Prins; Timothy F Cloughesy; Paul Mulholland; Marnix L Bosch
Journal:  J Transl Med       Date:  2018-05-29       Impact factor: 5.531

7.  Lymphatic outflow of cerebrospinal fluid is reduced in glioma.

Authors:  Qiaoli Ma; Felix Schlegel; Samia B Bachmann; Hannah Schneider; Yann Decker; Markus Rudin; Michael Weller; Steven T Proulx; Michael Detmar
Journal:  Sci Rep       Date:  2019-10-15       Impact factor: 4.379

8.  Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials.

Authors:  James F Curtin; Marianela Candolfi; Tamer M Fakhouri; Chunyan Liu; Anderson Alden; Matthew Edwards; Pedro R Lowenstein; Maria G Castro
Journal:  PLoS One       Date:  2008-04-23       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.